Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
Brandon Michael Henry, Chief Executive and Medical Officer at Aurelix Bio, shared a post on Linkedin about a recent article he and his colleague co-authored, published in Seminars in Thrombosis and Hemostasis, adding:
“Complement activation after AAV gene therapy is complex to interpret.
Early post-dose changes in platelets, C3/C4, or soluble C5b-9 do not automatically mean toxicity. In many cases, they may reflect expected pharmacodynamic engagement of innate immunity after vector exposure.
The clinical challenge is recognizing when that biology remains self-limited – and when it begins to evolve toward sustained complement amplification, endothelial injury, and thrombotic microangiopathy.
Our article in Seminars in Thrombosis and Hemostasis focuses on that interpretive boundary.
We provide a practical framework for integrating complement biomarkers with hematologic and renal markers, with emphasis on assay limitations, timing, trajectory, and clinical context.
The main point: gene therapy safety monitoring should not only ask whether complement activation is present.
It should ask what pattern it is following, whether it is resolving or escalating, and whether the broader clinical picture suggests expected biology or early vascular injury.”
Title: Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation
Authors: Brandon M Henry, Melvin Y Rincon, Giuseppe Lippi, Zoltán Prohászka, Stefanie Benoit
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!